-
Ortho Clinical Diagnostics Expands COVID-19 Test Offerings with Emergency Use Authorization of Total Nucleocapsid Antibody Test
americanpharmaceuticalreview
August 09, 2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, announced its qualitative COVID-19 Total N antibody test received US FDA emergency use authorization (EUA).
-
Ortho Clinical Diagnostics Expands COVID-19 Test Offerings with Emergency Use Authorization (EUA) of Total Nucleocapsid Antibody Test
prnasia
August 05, 2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, today announced its qualitative COVID-19 Total N antibody test received U.S. Food and Drug Administration EUA.
-
Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Critical Care Blood Testing Menu
prnasia
July 23, 2021
Ortho Clinical Diagnostics announced its VITROS® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho's VITROS® Critical Care menu, is now available in EU Countries, U.K. and several ASPAC and LATAM countries.*
-
Ortho Clinical Diagnostics Announces Partnership With Thermo Fisher Scientific
prnasia
July 08, 2021
Ortho Clinical Diagnostics, one of the world's largest pure-play, in-vitro diagnostics (IVD) companies, announced its distribution agreement with Thermo Fisher Scientific™ to provide and support MAS™ Quality Controls and LabLink xL™ Quality Assurance ...
-
Ortho Regenerative Technologies Receives Clinical Hold Letter From the U.S. FDA
americanpharmaceuticalreview
June 08, 2021
Ortho Regenerative Technologies Inc, a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced that it has received a clinical hold letter from the U.S. FDA related to its ...
-
Ortho Clinical Diagnostics Launches Quantitative COVID-19 IgG Antibody Test with CE Mark
prnewswire
May 06, 2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, announced its quantitative COVID-19 IgG antibody test achieved CE Mark.
-
Ortho Clinical Diagnostics Recognized With Prestigious Edison Award for Highly Accurate COVID-19 Solutions Capable of Mass-Scale Testing
prnasia
April 27, 2021
Ortho Clinical Diagnostics has been recognized with a prestigious silver 2021 Edison Award for its VITROS® COVID-19 testing solutions, helping labs meet demands of the pandemic with reliable mass-scale testing options.
-
Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media
prnasia
April 14, 2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, announced it received CE Marking for its VITROS® SARS-CoV-2 Antigen Test, initially launched in October 2020.
-
Ortho Announces Plans to Accelerate COVID-19 Antigen and Antibody Test Development Through New Contract with BARDA and the Department of Defense
prnasia
April 01, 2021
Ortho Clinical Diagnostics, one of the world's largest pure-play IVD companies, today announced that through its continued partnership with the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of Defense ...
-
Ortho's New COVID-19 Total, IgG Antibody Tests Receive CE Mark
americanpharmaceuticalreview
March 16, 2021
Ortho Clinical Diagnostics announced that its new VITROS® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS® Anti-SARS-CoV-2 IgG 2 Antibody assay received CE Mark for the qualitative and semi-quantitative detection of COVID-19 antibodies.